UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2115-9
Program Prior Authorization/Medical Necessity
Medication Ixinity® [coagulation factor IX (recombinant)]*
P&T Approval Date 11/2016, 11/2017, 11/2018, 11/2019, 11/2020, 11/2021, 11/2022,
11/2023, 11/2024
Effective Date 2/1/2025
1. Background
Ixinity [coagulation factor IX (recombinant)] is a human blood coagulation factor indicated in
adults and children with hemophilia B for on-demand treatment and control of bleeding episodes,
perioperative management, and for routine prophylaxis to reduce the frequency of bleeding
episodes.
Ixinity is not indicated for induction of immune tolerance in patients with hemophilia B.
2. Coverage Criteriaa:
A. Initial Authorization
1. Ixinity will be initially approved based on all of the following criteria:1-3
a. Diagnosis of hemophilia B
-AND-
b. One of the following:
(1) Submission of documentation showing failure to meet clinical goals (e.g.,
continuation of spontaneous bleeds, inability to achieve appropriate trough
level) after a trial of two of the following recombinant factor products:
(a) Benefix
(b) Rixubis
-OR-
(2) Submission of documentation showing history of hypersensitivity to two of the
following recombinant factor products:
(a) Benefix
(b) Rixubis
-OR-
(3) Physician attestation that patient would preferentially benefit from Ixinity
based on one of the following:
© 2024 UnitedHealthcare Services, Inc.
1
(a) Patient is at high risk for the development of inhibitors (e.g., family history
of inhibitors and success with product, current treatment less than 50 days,
high risk genetic mutation, history of initial intensive therapy greater than 5
days)
(b) Patient has developed inhibitors
(c) Patient has undergone immune tolerance induction/immune tolerance
therapy
-OR-
(4) Both of the following:
(a) Patient is currently on Ixinity therapy
-AND-
(b) Patient has not received a manufacturer supplied sample at no cost in
prescriber office, or any form of assistance from a Medexus Pharma
sponsored Ixinity Savings Program™ (e.g., sample card which can be
redeemed at a pharmacy for a free supply of medication) as a means to
establish as a current user of Ixinity*
* Patients requesting initial authorization who were established on therapy via the receipt of a
manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance
from a Medexus Pharma sponsored Ixinity Savings ProgramTM shall be required to meet
initial authorization criteria as if patient were new to therapy.
Authorization of therapy will be issued for 12 months.
B. Reauthorization
1. Ixinity will be approved based on the following criterion:
a. Documentation of positive clinical response to Ixinity therapy.
Authorization of therapy will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply
* Ixinity is typically excluded from coverage. Tried/Failed criteria may be in place. Please refer
to plan specifics to determine exclusion status.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
© 2024 UnitedHealthcare Services, Inc.
2
and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
4. References:
1. Ixinity [package insert]. Chicago, IL: Medexus Pharma, Inc.; March 2024.
2. Malec L, Shapiro AD. Hemophilia A and B: Routine management including prophylaxis. In:
UpToDate, Waltham, MA, 2024.
3. Hoots WK, Shapiro AD. Inhibitors in hemophilia: Mechanisms, prevalence, diagnosis, and
eradication. In: UpToDate, Waltham, MA, 2024.
4. MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia
and Selected Disorders of the Coagulation System. MASAC Document 284. April 11, 2024.
5. Benefix® [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals; November 2022.
6. Rixubis® [package insert]. Lexington, MA: Baxalta US Inc.; March 2023.
Program Prior Authorization/Medical Necessity - Ixinity
Change Control
11/2016 New program.
12/2016 Administrative change. Revised formatting.
11/2017 Annual review. Revised formatting without change to clinical intent.
Updated sample pack language and state mandate verbiage. Updated
reference.
11/2018 Annual review. No changes to clinical coverage criteria. Updated
references.
11/2019 Annual review. No changes to clinical coverage criteria. Updated
reference.
11/2020 Annual review. Updated background and references.
11/2021 Annual review with no changes to clinical coverage criteria. Updated
background and references.
11/2022 Annual review with no changes to clinical coverage criteria. Updated
name of manufacturer sponsored savings program. Updated references.
11/2023 Annual review with no changes to clinical coverage criteria. Updated
exclusion footnote to standard language and updated references.
11/2024 Annual review with no changes to clinical coverage criteria. Updated
background and references.
© 2024 UnitedHealthcare Services, Inc.
3